Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6402 posts found.

blood-1813410_960_720

FDA grants orphan drug designation to relapsed or refractory multiple myeloma candidate

August 6, 2025 Medical Communications, Research and Development Oncology, Sanofi, US Food and Drug Administration, myeloma

The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, Sanofi’s investigational monoclonal antibody developed for …
News

Five Facts about sleep and mental health

August 3, 2025 Medical Communications Five Facts, Psychiatry, insomnia, mental health, sleep, sleep disorders, sleep health

1 Rapid Eye Movement (REM) sleep enhances creative thinking and helps the brain form connections between ideas, supporting mental wellbeing …
Feature

Ryvu Therapeutics publishes research revealing potential drug combination for colorectal cancer

August 1, 2025 Medical Communications, Research and Development Oncology, Ryvu Therapeutics, colorectal cancer

Ryvu Therapeutics has published new findings from its ONCO Prime target discovery platform in Scientific Reports. The study reveals a …
News

NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer

July 30, 2025 Medical Communications, Research and Development AstraZeneca, NHS, National Institute for Health and Care Excellence, Oncology, dual immunotherapy, hepatocellular carcinoma, liver cancer

AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence (NICE) for its dual immunotherapy …
News
europe-1395916_640

Sanofi’s Sarclisa gains EU approval for multiple myeloma treatment

July 30, 2025 Medical Communications, Research and Development European Commission, Oncology, Sanofi, Sarclisa, european union, multiple myeloma

Sanofi has received approval from the European Commission for the use of Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and …
News

Universal Quantum partners with Open Quantum Institute to tackle endometriosis with new technology

July 29, 2025 Medical Communications, Research and Development Open Quantum Institute, Pain, Reproductive health, UN Sustainable Development Goals, United Nations, Universal Quantum, endometriosis, women's health

Based in Brighton, UK, Universal Quantum has joined the Open Quantum Institute (OQI) to explore how quantum computing could revolutionise …
News
Prescriptions image

Mental health medicine use in England reaches record high, NHSBSA report reveals

July 29, 2025 Manufacturing and Production, Medical Communications, Research and Development ADHD, COVID-19, NHS Business Services Authority, Psychiatry, antidepressants, antipsychotics, anxiolytics, barbiturate, dementia, hypnotics, mental health

According to new data published by the NHS Business Services Authority (NHSBSA), mental health prescriptions in England have reached their …
News

LDC strengthens healthcare focus with appointment of Amit Thaper as investment director

July 21, 2025 Business Services, Industry Associations, Research and Development Corporate, Inicio Health, Investment Director, LDC, RDi

LDC, the private equity arm of Lloyds Banking Group, has strengthened its healthcare expertise with the appointment of Amit Thaper …
Appointment

Boehringer Ingelheim and LEO Pharma partner to develop treatment for generalised pustular psoriasis

July 21, 2025 Medical Communications, Mergers and Acquisitions, Research and Development Boehringer Ingelheim, Dermatology, LEO Pharma, Spevigo, generalised pustular psoriasis, partnership, skin disease

Boehringer Ingelheim and LEO Pharma have partnered to commercialise and further develop Spevigo (spesolimab), a treatment for generalised pustular psoriasis …
News
Brain image

Johnson & Johnson submits FDA application for Caplyta to prevent schizophrenia relapse

July 18, 2025 Medical Communications, Research and Development CAPLYTA, Johnson & Johnson, Neurology, US Food and Drug Administration, neuroscience, new drug application, schizophrenia

Johnson & Johnson has submitted a supplemental New Drug Application to the US Food and Drug Administration (FDA) for Caplyta …
News
1200px-vaccine_image_1

EMA lifts temporary ban on chikungunya vaccine Ixchiq following safety review

July 18, 2025 Medical Communications Committee for Medicinal Products for Human USE, European Medicines Agency (EMA), Ixchiq, Pharmacovigilance Risk Assessment Committee (PRAC), Vaccine, Virology, chikungunya

After completing a safety review of Ixchiq – a vaccine for chikungunya – the European Medicines Agency’s (EMA) safety committee …
News
Vaccine image

FDA approves Moderna’s Spikevax for children at increased risk of COVID-19

July 16, 2025 Medical Communications COVID-19, Spikevax, US Food and Drug Administration, Vaccine, Virology

Moderna has been granted US Food and Drug Administration (FDA) approval for its COVID-19 vaccine, Spikevax, in children aged six …
News
clinical_trial-web

Pharvaris to report phase 3 data and submit New Drug Application

July 15, 2025 Medical Communications, Research and Development Pharvaris, Rare Diseases, US Food and Drug Administration, clinical trial, genetic condition, new drug application

Pharvaris has announced that its data from its phase 3 study of deucrictibant immediate-release capsules (IR) for the treatment of …
News
money_pills_2

VIVES Partners contributes to €84m funding for radiopharma company, Nuclidium

July 14, 2025 Medical Communications, Research and Development Nuclidium, Oncology, VIVES Funds, VIVES Partners, radiopharmaceuticals, radiotheranostics

VIVES Partners, the managing company of VIVES Funds, has announced that it will contribute to an €84m Series B financing …
News
bowel_cancer_screening

NICE recommends NHS use of mirikizumab for Crohn’s disease

July 11, 2025 Medical Communications, Research and Development Crohn’s disease, Gastrointestinal tract, Medicines and Healthcare products Regulatory Agency, NHS, National Institute for Health and Care Excellence (NICE), bowel disease, clinical trial

Eli Lilly (Lilly) has announced that the National Institute for Health and Care Excellence (NICE) has recommended mirikizumab (omvoh) for …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025